acalabrutinib + rifampin

**Acalabrutinib + rifampin** is a combination of two drugs: **acalabrutinib**, a selective covalent Bruton tyrosine kinase inhibitor used primarily for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia, and **rifampin**, a potent antibiotic and strong inducer of CYP3A enzymes[4][3]. Acalabrutinib's mechanism involves irreversible inhibition of Bruton tyrosine kinase, blocking B-cell receptor signaling and proliferation[4]. Rifampin is used mainly for tuberculosis, acting as a DNA-dependent RNA polymerase inhibitor in susceptible bacteria. When coadministered, rifampin markedly decreases acalabrutinib plasma exposure (both Cmax and AUC), due to CYP3A induction that accelerates acalabrutinib metabolism[3][2]. This combination is generally not recommended due to substantial reduction in acalabrutinib efficacy; if necessary, acalabrutinib dosage may be adjusted[2].

Brand names

calquencerifadin

Other names

acalabrutinibrifampicin